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Abstract
Background: Using electronic health record data, we hypothesized that larger reversal doses are used for patients
with deeper levels of neuromuscular blockade (NMB) as evidenced by the last recorded TOF measurement. We also
examined if dosing regimens reflect current practice guidelines of using ideal body weight (IBW) for NMB agents
and total body weight (TBW) for neostigmine.
Methods: This is a retrospective observational study of adult, ASA 1–4 patients who underwent general anaesthesia
and received non-depolarizing NMB agents between 01/01/2004 and 12/31/2013. For the primary outcome,
percentages of cases receiving neostigmine and median doses administered for each subjective train-of-four
(TOF) category were calculated. Secondary analyses evaluated associations between NMB dosing and neostigmine
administration based on Body Mass Index (BMI) categories.
Results: A total of 135,633 cases met inclusion criteria for the study. There was no clinically significant difference in
median neostigmine dosing based on last TOF count prior to reversal administration: 37.5 mcg/kg for TOF of 4/4 vs.
37.9 mcg/kg for TOF of 0/4 for the total neostigmine dose. Significantly higher number of patients with lower TOF
counts received additional neostigmine administration: 5.7 % for 0/4 vs. 1.5 % for 4/4 TOF counts. The median times to
extubation following neostigmine administration were clinically similar across TOF count categories. The median doses
for neostigmine based on TBW decreased with higher BMI categories and were significantly different between the
lowest and highest categories: 42.8 mcg/kg vs 30.8 mcg/kg for total doses (p < .0001) respectively. The percentages of
cases requiring reversal in addition to the initial dose increased with increasing BMI categories and were 2.1 % for BMI
< 18 vs. 3.3 % for BMI≥ 40. The total median dose of NMB agents in ED95 equivalents per IBW increased from 2.9 in
the Underweight category to 4.2 in the Class III Obese category. The majority of patients in the pancuronium subgroup
received very low ED95 equivalent dose of 0.1 and did not require reversal. Patients receiving cisatracurium were given
significantly higher median ED95 equivalent dose of 5.6 vs 2.8–3.9 compared to other intermediate acting NMB agents,
while receiving clinically similar doses of neostigmine.
Conclusions: Neither neostigmine dosing nor times to extubation were affected by the depth of the neuromuscular
blockade prior to reversal. The need for additional reversal, or rescue, correlated strongly with the depth of NMB. There
was significant variability in neostigmine dosing across the BMI categories. Underweight patients received relatively
lower NMB doses while simultaneously receiving relatively higher reversal doses, and the opposite was true for patients
with BMI >40.
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Background
Non-depolarizing neuromuscular blockade (NMB) is
commonly used to facilitate tracheal intubation and sur-
gical conditions in patients undergoing general anaesthe-
sia. It remains a mainstay of a balanced anaesthetic
technique despite advances in short acting volatile and
intravenous anaesthetics. Our understanding of the
prevalence and impact of residual postoperative NMB
has been greatly expanded in recent years [1, 2]. Even
mild levels of residual NMB decrease objective measures
of pulmonary function, increase the risk of aspiration
and airway obstruction, and worsen patient recovery
experience [3–6]. Residual neuromuscular blockade con-
tinues to be a widespread problem, affecting greater than
50 % of patients receiving NMB in normal practice, even
despite qualitative neuromuscular monitoring and the
use of neostigmine [7].
Although overwhelming majority of anaesthesiologists
surveyed in Europe and the United States believe that
either subjective or quantitative train-of-four (TOF)
monitoring may improve NMB management [8], neither
modality has been accepted as standard of care for
patients receiving neuromuscular blocking agents.
Among reasons cited for this lack of adoption of moni-
toring standards is significant practice variation in NMB
management that exists between countries, hospitals,
and individual practitioners [8, 9]. For example, accord-
ing to Naguib et al. [8], “surveys in Denmark, Germany,
the United Kingdom, and Mexico have suggested that
only 43, 28, 10, and 2 % of clinicians respectively, rou-
tinely use neuromuscular monitors of any kind.” In
addition to practice variations in NMB monitoring, there
are significant differences in the use of reversal agents at
the end of a surgical procedure. In their response to a
survey, 82 % of European and 65 % of American practi-
tioners have reported that they did not routinely admin-
ister a reversal agent following use of non-depolarizing
NMB drugs [8]. Current experts’ opinions suggest that
NMB monitoring should guide administration of NMB
agents [1, 4] as well as NMB reversal agents [10, 11].
However, a wide gap continues to exist between experts’
recommendations and current clinical practice of moni-
toring and NMB antagonism [9, 12]. Presently available
data on patterns of clinical practice are mainly limited to
small (<1000 patients) observational studies [13] and
survey results [8]. There are no recent data describing
the routine practice patterns of reversal and its relation-
ship to TOF monitoring. A better understanding of
practice patterns is needed in order to guide future rec-
ommendations and target efforts to improve clinical
practice and patient safety.
We used a large, granular intraoperative health record
dataset to identify current practices in neostigmine re-
versal. The primary objective of this study was to assess
whether dosing of neostigmine is related to the use of
subjective train-of-four (TOF) monitoring. We hy-
pothesized that reversal dosing is based upon the last
recorded subjective TOF assessment, with larger doses
used for patients with deeper levels of NMB as evi-
denced by lower TOF counts. We also examined
whether dosing regimens reflect current practice
guidelines of using ideal body weight (IBW) for NMB
agents [6, 14–16] and total body weight (TBW) for
neostigmine [14, 17, 18].
Methods
Study design and setting
This retrospective observational study of adult, ASA 1–4
patients who underwent general anaesthesia and re-
ceived non-depolarizing NMB agents at the University
of Michigan between 01/01/2004 and 12/31/2013. This
study received approval from the University of Michigan
Institutional Review Board (HUM00091819). The in-
formed consent was waived since all identifiable patient
elements were removed prior to data analysis. We ex-
cluded patients who were intubated prior to OR arrival,
patients transported to ICU following surgical proced-
ure, cardiac surgery, lung or liver transplantation, cases
where neostigmine was administered to facilitate intra-
operative neurologic monitoring with subsequent re-
dosing of NMB agents, and patients with myasthenia
gravis or those receiving pyridostigmine therapy. Moni-
toring of the neuromuscular blockade and TOF counts
were measured using the MiniStim® MS-IV (Life-Tech,
Stafford, TX) peripheral nerve stimulator. All data for
this study was gathered from the local University of
Michigan Health System (UMHS) anaesthesia informa-
tion management system (AIMS) and electronic health
record (EHR) (Centricity®, General Electric Healthcare,
Waukesha, WI). Basic patient anthropometrics, includ-
ing patient age, gender, body mass index (BMI), ASA
classification, emergent classification, and procedural in-
formation including case duration and surgical service
were extracted from the EHR. In addition, we collected
dose and time of administration information for neostig-
mine and all non-depolarizing NMB drugs: vecuronium,
rocuronium, atracurium, cisatracurium, and pancuro-
nium. We converted the doses of neuromuscular
blockers to effective doses required to reduce the
maximum twitch height by 95 % in 50 % of the
population (ED95 equivalents), corrected for ideal
body weight [6, 19, 20]. The following conversions
were used: vecuronium 0.05 mg/kg, rocuronium
0.3 mg/kg, atracurium 0.26 mg/kg, cisatracurium
0.05 mg/kg and pancuronium 0.07 mg/kg. Weight
correction for neostigmine was performed using total
body weight (TBW) [14, 17, 18]. Extubation times for
all included cases were extracted as well.
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Statistical analysis
All statistical analyses were performed using SPSS® ver-
sion 21 (Armonk, NY) and SAS® software, version 9.3
(Cary, NC). Missing data for each covariate were evalu-
ated - only case duration was missing more than 10 %
(21.1 %). Patients with missing or invalid height or
weight values were categorized as missing for the BMI
variable (3.5 %). Undocumented TOF data were analysed
as a separate category. To assess current usage of neo-
stigmine, patient and case characteristics were summa-
rized with frequency counts and percentages. Age was
normally distributed and reported as means and stand-
ard deviations, while surgical case duration (minutes)
was not normally distributed and reported as medians
and interquartile ranges. Overall trend in neostigmine
administration and subjective train-of-four (TOF) docu-
mentation was examined quarterly during the study
period. For the primary objective, percentages of cases
receiving neostigmine (initial dose, second dose, third
dose and total dose) and median doses administered for
each subjective train-of-four (TOF) category were calcu-
lated, as well as minutes between NMB dose, neostig-
mine administration and extubation. The relationship
between NMB dose in ED95 equivalents and TOF cat-
egories were also examined. Correlation coefficients, Pear-
son chi-square tests and Mann-Whitney tests quantified
associations and evaluated statistical significance. A p-value
of <0.05 was considered to be statistically significant.
Secondary analyses evaluated associations between NMB
dosing and neostigmine administration based on World
Health Organization Body Mass Index (BMI) categories.
Results
Table 1 shows patient and case characteristics for the
final 135,633 cases that met inclusion criteria from the
total of 166,195 cases studied. The stepwise exclusion
process is shown in Fig. 1. Monitoring of the neuromus-
cular blockade with subjective tactile TOF count has
been employed and documented in 83.9 % (113,869),
and reversal of NMB with neostigmine occurred in
86.4 % (117,123) of all cases that used non-depolarizing
Table 1 Patient and Case Characteristics
Patient/Case characteristics Did not receive
neostigmine
Received
neostigmine
Total N = 135,633 N = 18,510
(13.6 %)
N = 117,123
(86.4 %)
Agea 51 ± 18 52 ± 17
Surgical case duration (minutes)b 144 [87,238] 113 [69,177]
Emergent surgery 835 (4.5) 6095 (5.2)
ASA status
ASA class 1 or 2 10,976 (59.3) 68,910 (58.8)
ASA class 3 or 4 7534 (40.7) 48,213 (41.2)
Gender
Male 9484 (51.2) 63,165 (53.9)
Female 9026 (48.8) 53,957 (46.1)
World Health Organization BMI categories
Underweight, BMI <18.5 481 (2.7) 2456 (2.2)
Normal Weight, BMI 18.5–24.9 5466 (30.8) 3,2491 (28.7)
Overweight, BMI 25.0–29.9 5509 (31.0) 35,302 (31.2)
Class I Obesity, BMI 30.0–34.9 3346 (18.8) 22,634 (20.0)
Class II Obesity, BMI 35.0–39.9 1645 (9.3) 11,321 (10.0)
Class III Obesity, BMI ≥40 1326 (7.5) 8973 (7.9)
Last Recorded TOF
0/4 347 (1.9) 3557 (3.0)
1/4 478 (2.6) 6987 (6.0)
2/4 510 (2.8) 7751 (6.6)
3/4 425 (2.3) 7170 (6.1)
4/4 4187 (22.6) 82,457 (70.4)
Undocumented 12,563 (67.9) 9201 (7.9)
Surgical service
Dental 734 (4.0) 2904 (2.4)
General 2275 (12.3) 20,532 (17.5)
Gynecology 1000 (5.4) 11,742 (10.0)
Neurology 1937 (10.5) 9395 (8.0)
Ophthalmology 443 (2.4) 1630 (1.4)
Orthopedics 2843 (15.4) 18,273 (15.6)
Other 1296 (7.0) 8763 (7.5)
Otolaryngology 3691 (19.9) 8452 (7.2)
Plastics 1492 (8.1) 7814 (6.7)
Radiology 304 (1.6) 2056 (1.8)
Thoracic 533 (2.9) 5754 (4.9)
Transplant 419 (2.3) 4810 (4.1)
Urology 1093 (5.9) 10,657 (9.1)
Vascular 450 (2.4) 4341 (3.7)
Neuromuscular blockade agentc
Atracurium 1435 (7.8) 4528 (3.9)
Cisatracurium 3613 (19.5) 17,892 (15.3)
Table 1 Patient and Case Characteristics (Continued)
Pancuronium 1402 (7.6) 657 (0.6)
Rocuronium 1867 (10.1) 7069 (6.0)
Vecuronium 10,720 (57.9) 88,526 (75.6)
Multiple NMBAs 521 (2.8) 1544 (1.3)
Succinylcholine with NMBA 5891 (31.8) 28,608 (24.4)
ASA American Society of Anaesthesiologists, BMI body mass index, TOF train-
of-four, NMBA neuromuscular blockade agent
aAge is represented as mean ± standard deviation
bSurgical case duration is non-parametric and presented as median [25th to
75th percentile]
cCases may have received more than one type of neuromuscular blocking agent
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NMB agents. Of the 18,510 cases who did not receive
neostigmine, 69.7 % had no documentation of monitor-
ing. Contrary to our original hypothesis, there was no
clinically significant difference in median neostigmine
dosing based on last TOF count prior to reversal admin-
istration: 37.5 mcg/kg [range 3.8–125 mcg/kg] for TOF
of 4/4 vs 37.0 mcg/kg [range 5.0–95.7 mcg/kg] for TOF
0/4 for the initial neostigmine dose and 37.5 mcg/kg for
TOF of 4/4 vs. 37.9 mcg/kg for TOF of 0/4 for the total
neostigmine dose. However, significantly higher number
of patients with lower TOF counts received additional
neostigmine administration: 5.7 % for 0/4 TOF, 5.2 % for
1/4 TOF, 3.6 % for 2/4 TOF, 2.5 % for 3/4 TOF, and
1.5 % for 4/4 TOF counts (combined 2nd and 3rd neo-
stigmine doses). In addition to the 3.8-fold difference in
extra reversal between highest and lowest TOF categor-
ies (p < .0001), patients with TOF of 4/4 received a sig-
nificantly lower median neostigmine dose of 14.7 mcg/
kg [range 3.4–60.6 mcg/kg] compared to 20.0 mcg/kg
[range 5.6–61.3 mcg/kg] for patients in the TOF 0/4 cat-
egory (p < .0001) (based on 2nd neostigmine dose only).
These results are summarized in Table 2. There was lit-
tle correlation between the total dose of NMB agents in
ED95 equivalents and TOF categories: 3.5 for TOF of 0/
4 and 4/4 and 4.0 for TOF 1–3/4 (r = −0.08795). The
median times between administration of the first rever-
sal dose and extubation were not clinically significant
between TOF categories: 12.7 min for 4/4 TOF and
12.0 min for 0/4 TOF counts. These findings are sum-
marized in Table 3. The trends in neostigmine use and
TOF monitoring are shown in Fig. 2 and demonstrate
increase in percentage of cases getting reversal from
76.2 % in 2004 to 92.2 % in 2013, as well as a significant
increase from 51.9 to 79.0 % in cases with last TOF
count of 3 or 4 out of 4 prior to reversal. The overall use
of subjective TOF monitoring has increased from 73.0 to
87.8 % over the ten year study period.
The median doses for neostigmine based on TBW
decreased with higher BMI categories and were sig-
nificantly different between the lowest (Underweight,
BMI <18.5) and highest (Class III Obese, BMI ≥ 40)
categories: 42.6 mcg/kg vs 30.5 mcg/kg for initial doses
(p < .0001) and 42.8 mcg/kg vs 30.8 mcg/kg for total doses
(p < .0001) respectively (Table 2). The percentages of cases
requiring reversal in addition to the initial dose (2nd and
3rd neostigmine doses combined) increased with increasing
Fig. 1 Study Population Breakdown. NMDA = Neuromuscular Blocking Agent
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Table 2 Neostigmine dose by last documented Train of Four (TOF) prior to reversal and Body Mass Index (BMI) category for cases receiving Neostigmine
Cases receiving
first dose
Initial dose (mcg/kg) Cases receiving
second dose
Time between
first and second
doses (minutes)
Second dose
(mcg/kg)
Cases receiving
third dose
Time between second
and third doses (minutes)
Third dose (mcg/kg) Total dose (mcg/kg)
Na Median [IQR] N (%)a Median [IQR] Median [IQR] N (%)a Median [IQR] Median [IQR] Median [IQR]
Last TOF prior to reversal
0/4 3520 37.0 [30.6, 42.4] 192 (5.5) 6 [2, 12] 20.0 [14.2, 28.1] 7 (0.2) 5 [3, 8] 22.4 [13.0, 23.9] 37.9 [30.9, 43.7]
1/4 6956 37.1 [30.8, 42.8] 338 (4.9) 6 [2, 11] 17.3 [11.6, 24.8] 18 (0.3) 6 [3, 14] 16.8 [13.8, 27.8] 37.8 [31.3, 43.9]
2/4 7713 37.2 [30.9, 42.2] 267 (3.5) 7 [2, 13] 15.8 [10.8, 25.0] 11 (0.1) 7 [2, 9] 11.1 [8.1, 18.1] 37.6 [31.1, 42.7]
3/4 7133 36.8 [30.7, 41.9] 166 (2.3) 5 [1, 12] 14.5 [10.1, 22.3] 11 (0.2) 7 [3, 10] 14.7 [10.6, 17.9] 37.0 [30.8, 42.3]
4/4 81,958 37.5 [30.6, 41.7] 1136 (1.4) 5 [1, 12] 14.7 [9.9,22.1] 73 (0.1) 3 [1, 6] 11.3 [9.3, 15.2] 37.5 [30.6, 41.7]
Undocumented 9105 34.5 [29.4, 41.1] 217 (2.4) 6 [2, 11] 17.9 [11.1, 26.7] 10 (0.1) 9 [4, 16] 14.1 [11.6, 17.5] 35.0 [29.4, 41.5]
WHO BMI categoryb
Underweight 2456 42.6 [36.6, 49.2] 50 (2.0) 10 [4, 15] 22.7 [19.3, 31.3] 1 (0.0) 15 [15, 15] 24.1 [24.1, 24.1] 42.8 [36.8, 50.0]
Normal weight 32,491 39.4 [33.3, 44.4] 574 (1.8) 6 [2, 12] 19.2 [14.4, 29.9] 31 (0.1) 6 [2, 9] 17.2 [14.3, 23.9] 39.7 [33.4, 44.8]
Overweight 35,302 37.5 [31.1, 41.7] 609 (1.7) 6 [1, 11] 15.6 [11.9, 25.5] 42 (0.1) 5 [2, 10] 13.2 [10.8, 20.0] 37.6 [31.3, 41.7]
Class I obese 22,634 35.3 [29.7, 40.4] 488 (2.2) 5 [1, 13] 14.4 [10.1, 22.2] 26 (0.1) 3 [1, 7] 10.5 [9.4, 12.8] 35.7 [29.8, 40.7]
Class II obese 11,321 32.7 [28.1, 39.7] 258 (2.3) 4 [1, 11] 11.9 [9.2, 19.6] 14 (0.1) 2 [1, 5] 10.3 [9.0, 13.6] 33.1 [28.4, 40.0]
Class III obese 8973 30.5 [25.0, 37.0] 284 (3.2) 3 [0, 9] 10.4 [7.5, 16.7] 12 (0.1) 4 [1,11] 8.1 [7.0, 14.3] 30.8 [25.3, 37.5]
TOF train-of-four, WHO World Health Organization, BMI body mass index
aOnly among patients with TBW between 40 and 250 kg and receiving neostigmine
bOnly among patients with BMI between 10 and 80
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BMI categories and were 2.1 % for BMI < 18 vs. 3.3 %
for BMI ≥ 40. The total median dose of NMB agents
in ED95 equivalents per IBW increased from 2.9 in
the Underweight category to 4.2 in the Class III
Obese category (Table 3). The variations in the ad-
ministration of neostigmine and NMB agents across
different BMI categories are represented graphically in
Fig. 3. The time intervals between initial neostigmine
administration and extubation were clinically similar
(within one minute) across the BMI categories.
Analysis of subgroups based on individual NMB
agents, showed that only 31.9 % of patients receiving
pancuronium were reversed with neostigmine, com-
pared to 75.9–89.2 % for other non-depolarizing
NMB agents. The median dose of pancuronium in
ED95 equivalents was 0.1 in the group that did not
Table 3 Neuromuscular Blocking Agent dose by last documented Train-of-Four prior to reversal and Body Mass Index category
Total dose of NMB
(ED 95 equivalent)a
Last dose of NMB
(ED 95 equivalent)a
Time between last NMB & first
neostigmine dose (minutes)b
Time between first neostigmine
dose & extubation (minutes)b
Median [IQR] Median [IQR] Median [IQR] Median [IQR]
Last TOF prior to reversal
0/4 3.5 [2.4, 5.2] 1.3 [0.7, 2.4] 52.0 [36.0, 80.3] 12.0 [8.0, 18.0]
1/4 4.0 [2.8, 5.8] 0.8 [0.5, 1.7] 42.0 [29.0, 59.0] 12.5 [8.0, 19.0]
2/4 4.0 [2.8, 5.9] 0.7 [0.4, 1.4] 43.6 [31.0, 61.0] 12.8 [8.0, 18.9]
3/4 4.0 [2.7, 5.8] 0.7 [0.4, 1.5] 49.0 [35.0, 68.0] 12.4 [8.0, 19.0]
4/4 3.5 [2.5, 5.3] 0.8 [0.5, 1.8] 65.0 [44.0, 95.0] 12.7 [8.0, 19.0]
Undocumented 3.3 [2.2, 5.1] 0.7 [0.4, 1.8] 43.0 [24.0, 76.0] 12.0 [7.3, 18.0]
WHO BMI categoryc
Underweight 2.9 [2.0, 4.4] 0.8 [0.5, 1.6] 57.4 [39.0, 86.4] 13.8 [9.0, 21.0]
Normal Weight 3.3 [2.2, 4.9] 0.8 [0.4, 1.8] 58.0 [39.0, 86.0] 13.0 [8.0, 19.0]
Overweight 3.6 [2.5, 6.3] 0.7 [0.4, 1.8] 58.9 [39.0, 87.9] 12.1 [8.0, 19.0]
Class I Obese 3.8 [2.7, 5.7] 0.8 [0.5, 1.9] 59.0 [39.0, 87.5] 12.1 [8.0, 19.0]
Class II Obese 4.0 [2.7, 5.9] 0.8 [0.5, 2.0] 58.5 [39.1, 88.1] 12.3 [8.0, 19.0]
Class III Obese 4.2 [2.9, 6.3] 0.8 [0.5, 1.9] 57.0 [38.0, 85.0] 12.9 [8.0, 19.0]
ED95 effect dose for which 95 % of the population exhibits the effect, TOF train-of-four, WHO World Health Organization, BMI body mass index
aOnly among patients with IBW between 40 and 250 kg
bOnly among patients receiving neostigmine
cOnly among patients with BMI between 10 and 80
Fig. 2 Trend in Neostigmine use and Train of Four (TOF) documentation by quarter, May 2004 - December 2013
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receive reversal, likely consistent with practice of pre-
curarization (Table 4). The median reversal dose for
patients receiving pancuronium was significantly
higher than neostigmine doses for intermediate acting
neuromuscular blockers: 47.2 mcg/kg vs 33.7–38.2
mcg/kg. Subgroup analysis also demonstrated that pa-
tients receiving cisatracurium had significantly higher
median ED95 equivalent dose of 5.6 vs 2.8–3.9 com-
pared to other intermediate acting NMB agents, while
receiving clinically similar doses of neostigmine 36
mcg/kg vs 33.7–38.2 mcg/kg (Table 4, no succinyl-
choline). Similar trend was observed for subgroups
receiving cisatracurium and no reversal, both with
and without succinylcholine.
Discussion
In this large, single-centre study we demonstrate that
contrary to the published guidelines and our hypoth-
esis, there was little correlation between monitoring
of the depth of neuromuscular blockade and dosing
of neostigmine in clinical practice. The total neostig-
mine dose tended to be weight-based and fell into a
narrow clinical range of 37.0–37.9 mcg/kg across all
TOF categories and was significantly lower than the
“standard dose” of 50 mcg/kg reported by other
sources [12, 19] and recommended for reversing
TOF counts between 1 and 3 [10]. Although our
single centre database may reflect institutional bias
and site-specific clinical care processes associated
with a large academic medical centre with an anaes-
thesiology training program, our median reversal
doses were remarkably similar to the mean neostig-
mine dose of 32 mcg/kg recently reported by Roach
and Smith [12].
The median time from reversal administration to extu-
bation also did not change significantly (12.0–12.8 min
range) based on the TOF count prior to reversal.
Together these findings suggest that when using non-
depolarizing NMB agents, the vast majority of providers
employed TOF monitoring and administered reversal,
however neither neostigmine dosing nor time to extuba-
tion were affected by the depth of the neuromuscular
blockade prior to reversal. One parameter that corre-
lated strongly with the depth of NMB was the need for
additional reversal, or rescue, when initial dose failed to
produce desired clinical effect. In addition, 3.0 % of
patients received inappropriate reversal when the neo-
stigmine was administered with TOF count of 0/4
[10]. This is markedly lower than reported in recent
literature from other single-centre analyses [6]. It was
encouraging to see that the overall number of cases
receiving clinically-indicated neostigmine has in-
creased throughout the study period, as well as the
percentage of cases with TOF counts of 3–4/4. We
Fig. 3 Variation in median dose of intermediate duration neuromuscular blocking agents (NMBs) indexed to Ideal Body Weight (IBW) and
Neostigmine dose indexed to Total Body Weight (TBW) across Body Mass Index (BMI) categories [6, 14–17]. * Cisatracurium doses represent the
total amount of drug given (infusions and boluses)
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Table 4 Subgroup analysis of individual neuromuscular blocking agents
Cases receiving neostigmine Cases not receiving neostigmine
Neuromuscular
blocking agent
Cases receiving
NMB
NMB total dose
(ED 95 Equivalent)a
Time between last NMB
& extubation (minutes)
Total dose of neostigmine
(mcg/kg)b
Cases receiving NMB NMB total dose
(ED 95 Equivalent)a
Time between last
NMB & extubation
(minutes)
N Median [IQR] Median [IQR] Median [IQR] N Median [IQR] Median [IQR]
No Succinylcholine Atracurium 2981 3.9 [2.6, 5.9] 67.0 [50.0, 90.0] 33.7 [29.7, 41.7] 906 2.9 [2.1, 4.7] 119.0 [85.0, 174.0]
Cisatracurium 12,905 5.6 [3.9, 8.3] 73.0 [53.0, 102.0] 36.0 [30.2, 42.4] 2596 4.6 [3.1, 7.1] 136.0 [90.0, 204.0]
Pancuronium 134 1.3 [0.1, 2.3] 99.5 [62.0, 161.0] 47.2 [35.8, 61.7] 48 0.1 [0.1, 0.1] 210.5 [150.5, 265.0]
Rocuronium 5602 2.8 [2.2, 4.0] 83.0 [59.0, 117.0] 36.6 [29.8, 41.7] 1510 2.4 [1.8, 3.4] 126.0 [89.0, 174.0]
Vecuronium 65,708 3.4 [2.4, 4.9] 76.0 [55.0, 108.0] 38.2 [31.5, 42.2] 7343 2.8 [2.0, 4.5] 145.0 [93.0, 233.0]
Multiple NMBAs 1185 5.9 [4.4, 8.0] 71.0 [52.0, 101.0] 39.0 [32.1, 44.9] 216 6.6 [4.8, 8.6] 92.0 [37.5, 162.5]
Succinylcholine Atracurium 1407 3.4 [2.2, 5.4] 60.0 [46.0, 84.0] 31.8 [28.2, 39.0] 439 2.5 [1.5, 4.4] 95.0 [65.0, 141.0]
Cisatracurium 4591 4.8 [2.9, 7.6] 65.0 [49.0, 88.0] 32.7 [28.8, 40.0] 864 4.1 [2.2, 7.5] 106.0 [68.0, 153.0]
Pancuronium 63 2.1 [1.2, 2.6] 96.0 [74.0, 140.0] 37.0 [31.6, 48.0] 1025 0.1 [0.1, 0.1] 101.5 [60.0, 181.5]
Rocuronium 674 2.1 [1.3, 3.0] 62.0 [42.0, 87.0] 32.1 [26.1, 39.4] 232 1.0 [0.3, 2.0] 81.0 [53.0, 129.0]
Vecuronium 21,514 3.0 [1.9, 4.7] 67.0 [49.0, 93.0] 36.7 [30.0, 41.3] 3026 2.6 [1.3, 4.8] 115.0 [67.0, 195.0]
Multiple NMBAs 359 3.6 [2.2, 5.6] 65.0 [46.0, 94.0] 35.1 [30.0, 41.3] 305 3.0 [1.5, 6.3] 82.0 [41.0, 154.0]
aOnly among patients with IBW between 40 and 250 kg
bOnly among patients with TBW between 40 and 250 kg
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speculate that this reflects increased awareness of the
residual neuromuscular blockade by clinical providers
in recent years.
Although median values for neostigmine did not
change much based on last TOF counts, there was
significant variability in its dosing across the BMI cat-
egories. Both categories at the extremes of the BMI
spectrum have been shown to be at risk for residual
neuromuscular blockade [7] or postoperative pulmon-
ary complications: 6.39 % for BMI < 18 and 4.15 %
for BMI > 35 vs. 3.61 % for normal weight patients
[6]. A recent study by Sasaki et al. [21] demonstrated
that high-dose or unwarranted use of neostigmine
may be associated in increased incidence of postoper-
ative respiratory events. Further evidence that reversal
with acetylcholine inhibitors may be undesirable in
the absence of neuromuscular blockade was provided
by Herbstreit et al. [22], supporting the idea that re-
versal dose must be closely matched to the depth of
the existing NMB [10]. Our data suggest that differ-
ent mechanisms may be responsible for the higher re-
ported incidence of adverse events in underweight
and severely overweight patients. As Fig. 3 demon-
strates, underweight patients tend to receive relatively
lower NMB doses while simultaneously receiving rela-
tively higher reversal doses, potentially placing them
at an increased risk from excessive use of acetylcho-
line inhibitors. The opposite is true for patients with
BMI > 40, who may be at higher risk due to overdos-
ing of NMB and relative underdosing of neostigmine.
This situation may not be unique to neostigmine, as
both recurarization and incomplete reversal with ap-
propriate does of sugammadex have been reported in
obese patients receiving high doses of rocuronium
[23, 24]. Our findings of potential NMB depth/rever-
sal mismatch across BMI categories raise interesting
questions and warrant further investigation through
prospective trials.
There are several limitations inherent in this obser-
vational analysis of routinely collected intraoperative
electronic health record data. First, the analyzed data-
set of patient characteristics and intraoperative docu-
mentation did not allow for correlation between dose
of neostigmine and postoperative clinical outcomes
such as reintubation, pneumonia, or atelectasis. In
addition, because the standard process of care at our
centre, and many others, does not include monitoring
of objective acceleromyography, the analysis cannot
establish whether the dose of neostigmine is associ-
ated with complete reversal. Another limitation of our
analysis is the inability to evaluate the impact of com-
mon medical comorbidities, the use of volatile
anesthesia, or site of monitoring on the patterns of
reversal.
Our study provides important information on current
clinical patterns of use of neostigmine and exposes dis-
crepancies between existing guidelines and actual clinical
practice. In may be useful to incorporate our findings of
potential NMB depth/reversal mismatch into design of
future trials, as well as to influence future clinical guide-
lines, since patients in different BMI categories may re-
quire different interventions to improve safety of
neuromuscular blockade.
Conclusions
Contrary to our initial hypothesis, deeper levels of neuro-
muscular blockade were not associated with larger rever-
sal doses. The median neostigmine dosing remained
clinically similar across different levels of NMB as defined
by the TOF counts. The median times to extubation fol-
lowing neostigmine administration were also similar for
all TOF count categories. On the other hand, there was
significant variability in neuromuscular blocker and neo-
stigmine dosing across different BMI categories. The total
median dose of neuromuscular blocking agents increased
with increasing BMI, while the median dose of neostig-
mine decreased with increasing BMI.
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